Expert Review of Pharmacoeconomics & Outcomes Research

Taylor & Francis

Journal websitePeer review: Peer review
Evaluation status available after sign-in

About the journal

Expert Review of Pharmacoeconomics & Outcomes Research is a journal published by Taylor & Francis in United Kingdom. It is listed in MEDLINE according to the sources read. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.

Basic facts

Publisher
Taylor & Francis
ISSN
1473-7167 · 1744-8379
Country
United Kingdom
Access
Not open access / not declared
Declared peer-review model
peer_review

Index listings

  • MEDLINE · 2009-01-01
Indexing
MEDLINE
APC
—
Declared review time (DOAJ)
—
Activity (OpenAlex)
Active — latest works 2026
PublishLens list status
Shown after sign-in
Counts for promotion at your university?
Choose your university and rank below ↓

Methodology signals (dated facts from their sources)

Details of the evaluation under the published methodology are shown to signed-in users (free).

Create a free account to view the evaluation

Journal profile

Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.

Works in OpenAlex

2322

Last recorded publication year

2026

Reported by OpenAlex in 1 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core

h-index

80

i10-index

823

From OpenAlex open data (CC0).

Editorial & policy5
Observed digital preservation (Keepers registry)— snapshot 2026-10-05
CLOCKSSPortico
Norwegian register (HK-dir)— 2026
Level 1 — approved scholarly channel
Open references deposited at Crossref
99%
ORCID iDs in current deposits
50%
Enrolled in Crossref Similarity Check
✓
Deposits licence metadata at Crossref
✓
Identity & continuity3
Alternate titles
Expert review of pharmacoeconomics and outcomes research
Source type
journal
NLM unique ID (PubMed)
101132257
Classification(no data)

No data available to the platform for this group

No platform data for: Classification — absence is not a judgment about the journal.

Subject areas

  • Health Systems, Economic Evaluations, Quality of Life
  • Health Systems, Economic Evaluations, Quality of Life
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Pharmaceutical Economics and Policy
  • Pharmaceutical Economics and Policy
  • Economic and Financial Impacts of Cancer
  • Economic and Environmental Valuation
Show all subjects (75)
  • Economic and Financial Impacts of Cancer
  • Economic and Financial Impacts of Cancer
  • Healthcare Policy and Management
  • Healthcare Policy and Management
  • Healthcare Policy and Management
  • Healthcare Systems and Reforms
  • Cancer survivorship and care
  • Global Health Care Issues
  • Global Health Care Issues
  • Medication Adherence and Compliance
  • Medication Adherence and Compliance
  • Delphi Technique in Research
  • Healthcare cost, quality, practices
  • Healthcare cost, quality, practices
  • Economic and Environmental Valuation
  • Economic and Environmental Valuation
  • Biosimilars and Bioanalytical Methods
  • Biosimilars and Bioanalytical Methods
  • Rheumatoid Arthritis Research and Therapies
  • Rheumatoid Arthritis Research and Therapies
  • Cancer survivorship and care
  • Cancer survivorship and care
  • Pharmaceutical studies and practices
  • Pharmaceutical studies and practices
  • Pharmaceutical Practices and Patient Outcomes
  • Pharmaceutical Practices and Patient Outcomes
  • Medication Adherence and Compliance
  • Science, Research, and Medicine
  • Science, Research, and Medicine
  • Statistical Methods in Clinical Trials
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Pharmacy and Medical Practices
  • Musculoskeletal pain and rehabilitation
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Biosimilars and Bioanalytical Methods
  • Pharmaceutical Practices and Patient Outcomes
  • Healthcare Systems and Reforms
  • Healthcare Systems and Reforms
  • Asthma and respiratory diseases
  • Asthma and respiratory diseases
  • Asthma and respiratory diseases
  • Chronic Disease Management Strategies
  • Biotechnology and Related Fields
  • Rheumatoid Arthritis Research and Therapies
  • Chronic Disease Management Strategies
  • Biotechnology and Related Fields
  • Diabetes Treatment and Management
  • Healthcare cost, quality, practices
  • Mental Health Treatment and Access
  • Multiple Sclerosis Research Studies
  • Multiple Sclerosis Research Studies
  • Pharmaceutical industry and healthcare
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Treatments and Mutations
  • Childhood Cancer Survivors' Quality of Life
  • Childhood Cancer Survivors' Quality of Life
  • Meta-analysis and systematic reviews
  • Statistical Methods in Clinical Trials
  • Statistical Methods in Clinical Trials
  • Global Health Care Issues
  • Blood Pressure and Hypertension Studies
  • Pneumonia and Respiratory Infections
  • Blood Pressure and Hypertension Studies
  • Pneumonia and Respiratory Infections
  • Health Education and Validation
  • Bone health and treatments

Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.

Loading community confirmations…
How do we evaluate?Publisher of this journal? Appeal a derived assessment or request a factual correction

The journal's record in other sources:Web of Science MJLDOAJ

Everything shown here is produced automatically from named sources (DOAJ, OpenAlex, Crossref, PubMed, the Norwegian register) as of its capture date, with no human editing. Facts appear as recorded at the source; derived scores (PCI, PTD, PublishLens score) follow a published methodology. Not a judgement on the journal, not an official accreditation, not advice.

Wrong items are corrected automatically by re-reading the source (24 h for daily sources, 7 days for weekly ones) with a dated change log, and each item links to its source record. PublishLens-derived assessments are contested through the appeals mechanism (15 working days). Appeals · Indicator guide

Norwegian register data: Kanalregisteret (HK-dir, Norway) — CC BY 4.0 / NLOD — adapted: level extracted per year · OASPA member list — CC BY

Last automated source read: